Vera Therapeutics Appoints Matt Skelton as Chief Commercial Officer

Vera Therapeutics, Inc. (Nasdaq:
VERA), a late clinical-stage biotech company focused on immunological diseases, announced the appointment of Matt Skelton as Chief Commercial Officer on January 28, 2026, effective immediately.12

Skelton joined Vera over a year ago as Executive Vice President, Commercial and previously scaled Seagen's commercial organization from one to four products, with prior roles at Amgen and Eli Lilly.134

The appointment supports preparations for the potential commercial launch of atacicept, an investigational treatment for IgA nephropathy (IgAN) with FDA Breakthrough Therapy Designation and Priority Review; PDUFA target action date is July 7, 2026.23

CEO Marshall Fordyce highlighted Skelton's experience in building commercial organizations for atacicept's launch; Skelton emphasized atacicept's dual BAFF/APRIL inhibition and self-administration profile.12

Sources:

1. https://www.globenewswire.com/news-release/2026/01/28/3227518/0/en/Vera-Therapeutics-Announces-Appointment-of-Matt-Skelton-to-Chief-Commercial-Officer.html

2. https://www.quiverquant.com/news/Vera+Therapeutics+Appoints+Matt+Skelton+as+Chief+Commercial+Officer+Amid+Commercial+Launch+Preparations+for+Atacicept

3. https://www.investing.com/news/company-news/vera-therapeutics-promotes-matt-skelton-to-chief-commercial-officer-93CH-4469907

4. https://www.marketscreener.com/news/vera-therapeutics-announces-appointment-of-matt-skelton-as-chief-commercial-officer-effective-janua-ce7e5bd9df81f526